Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

We investigated the emergence of cytomegalovirus (CMV) ganciclovir-resistance mutations in 301 high-risk solid-organ transplant (SOT) recipients after oral prophylaxis, for 100 days, with either valganciclovir or ganciclovir. For patients treated with ganciclovir, the incidence of CMV UL97 mutations was 1.9% (2/103) at the end of prophylaxis and 6.1% (2/33) for patients with suspected CMV disease up to 1 year after transplantation. No resistance mutations were detected in samples from valganciclovir-treated patients. Dual polymerase (UL54) and UL97 resistance mutations were not seen. Valganciclovir was associated with negligible risk of resistance and thus constitutes a useful alternative to ganciclovir prophylaxis for CMV in high-risk SOT recipients.

Full Text

Duke Authors

Cited Authors

  • Boivin, G; Goyette, N; Gilbert, C; Roberts, N; Macey, K; Paya, C; Pescovitz, MD; Humar, A; Dominguez, E; Washburn, K; Blumberg, E; Alexander, B; Freeman, R; Heaton, N; Covington, E

Published Date

  • May 1, 2004

Published In

Volume / Issue

  • 189 / 9

Start / End Page

  • 1615 - 1618

PubMed ID

  • 15116297

International Standard Serial Number (ISSN)

  • 0022-1899

Digital Object Identifier (DOI)

  • 10.1086/382753


  • eng

Conference Location

  • United States